HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target

Seaport Therapeutics Reports Phase 1 Results; GlyphAllo At 375 mg Meets Primary Endpoint With No Driving Impairment; 250 mg Dose Also Achieves Key Secondary Endpoint

Trial met its primary endpoint, showing that evening dosing of GlyphAllo at 375 mg did not impair next-morning driving performance compared to placebo on Day 5, following multiple-day dosingKey secondary endpoint also

Seaport Therapeutics shares are trading higher after Jones Trading initiated coverage on the stock with a Buy rating and announced a $32 price target.

Jones Trading Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $32

Jones Trading analyst Justin Walsh initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Buy rating and announces Price Target of $32.